The importance of identifying the intermediate
|
|
- Louisa Kelley
- 7 years ago
- Views:
Transcription
1 THE INTERMEDIATE STAGE OF AMD: WHY SHOULD WE IDENTIFY IT AND WHAT CAN WE DO ABOUT IT?* Jennifer I. Lim, MD ABSTRACT Early identification of the intermediate stage of age-related macular degeneration (AMD) is a key component toward preventing progression to advanced AMD and saving visual acuity. Preventive strategies include education of patients about self-monitoring for symptoms of metamorphopsia and scotomas and the importance of reporting these signs promptly; initiation of highdose antioxidant vitamins combined with zinc, as used in the Age-Related Eye Disease Study (AREDS); and routine monitoring of patients at risk for early signs of choroidal neovascularization. This article reviews the AREDS definition and risk stratification of intermediate AMD, the role of antioxidants and zinc in reducing structural and functional risk, and the impact of smoking on AMD. It also addresses the roles of patient selfmonitoring and periodic follow-up by the comprehensive ophthalmologist, with special emphasis on the Amsler grid and preferential hyperacuity perimeter testing. Lastly, the article discusses the findings of several laser studies that were undertaken to determine whether laser eradication of drusen could prevent progression of the intermediate stage of AMD to advanced AMD. (Adv Stud Ophthalmol. 2007;4(2):32-36) *Based on a presentation at a symposium held at the American Academy of Ophthalmology Annual Meeting in Las Vegas, Nevada, on November 12, Professor of Ophthalmology, Medical and Surgical Retina, Medical Director of Clinical Trials, University of Southern California Keck School of Medicine, Doheny Retina Institute of the Doheny Eye Institute, Los Angeles, California. A d d ress correspondence to: Jennifer I. Lim, MD, Professor of Ophthalmology, Medical and Surgical Retina, Medical Director of Clinical Trials, University of Southern California Keck School of Medicine, Doheny Retina Institute of the Doheny Eye Institute, 1450 San Pablo Street, Los Angeles, CA jlim@doheny.org. The importance of identifying the intermediate stage of age-related macular degeneration (AMD) in a comprehensive ophthalmology practice cannot be ove re m- p h a s i zed. Because patients with the intermediate stage of AMD are at increased risk of pro g re s s i n g to advanced AMD, early detection of the intermediate stage is, quite simply, a major key to saving vision. In the United States alone, 8 million people older than 55 years of age have intermediate AMD, and of them will develop advanced AMD (ie, the presence of choroidal neovascularization [CNV] or geographic atrophy of the foveal center) each year. 1 Clearly, detecting the intermediate stage of AMD before it progresses is crucial. DEFINITION AND RISK ASSESSMENT As defined in the Age-Related Eye Disease Study (AREDS), the intermediate stage of AMD is characterized by the presence of numerous medium-sized drusen or at least 1 large druse or noncentral geographic atrophy on funduscopic examination. 2 Large is defined as 125 µm or greater, or approximately the diameter of a vein as it emerges from the optic nerve; medium as between 63 mm and 124 µm; and numerous as more than 20 indistinct or more than 50 distinct drusen. Eyes with any of these features are at i n c reased risk of pro g ression to advanced AMD. Affected patients may be asymptomatic, may have mildly blurred central vision, or may complain of the need for more light. The risk of progression from the intermediate stage of AMD to advanced AMD can be assessed clinically using a simplified 5-point scale (0 4). This scale was developed by AREDS investigators and based on grading of fundus photographs of patients who participated in AREDS and progressed to advanced AMD 32 Vol. 4, No. 2 n March 2007
2 (Table 1). 3 Large drusen size and abnormalities of the retinal pigment epithelium, both of which are easily identifiable on funduscopy, were particularly predictive of progression and are thus included in the risk scoring scale. PREVENTIVE STRATEGIES Once the intermediate stage of AMD is identified, s e veral strategies may be employed to reduce the risk of p ro g ression to advanced AMD. These strategies include educating patients about self-monitoring their vision and re p o rting any changes pro m p t l y, initiating therapy with the vitamin and mineral supplements evaluated in A R E D S, 2 modifying some of the risk factors that are associated with AMD, and routinely monitoring patients at risk for signs of asymptomatic pro g re s s i o n. VITAMIN/MINERAL SUPPLEMENTS In 2001, AREDS investigators evaluated the effect of high-dose antioxidants (vitamins C and E and beta c a rotene) and zinc on AMD pro g ression and visual acuity in patients with the intermediate stage of AMD in 1 or both eyes or advanced AMD in 1 eye only. 2 They found that the supplements, which we re given as 2 oral tablets twice a day with meals (Table 2), prov i d- ed both structural and functional protection in these patients. St ructural protection was evidenced by an absolute reduction in the 5-year risk of pro g re s s i o n (clinical fundus findings) of 11% (from 43% 32%), which re p resents a re l a t i ve risk reduction of 25%. Protection of visual function was evidenced by a re l a- t i ve reduction of 27% for vision loss (ie, loss of 1 5 letters or 3 lines). Based on these findings, the AREDS inve s t i g a- tors recommended that antioxidants and zinc be g i ven, in the doses listed in Table 2, to patients with e x t e n s i ve intermediate drusen, 1 or more large d rusen, noncentral geographic atrophy in 1 or both e yes, or advanced AMD or visual acuity loss due to AMD in 1 eye. 2 It should be noted that the re c o m- mendations are slightly different for patients who smoke. Studies have found that smokers are at considerably higher risk for AMD than nonsmokers. 4-7 Howe ve r, high doses of beta carotene increase the a l ready significant risk of lung cancer in smokers, 2, 8 thus the use of high-dose beta carotene in patients with the intermediate stage of AMD who smoke is not re c o m m e n d e d. OTHER NUTRITIONAL APPROACHES Other nutritional approaches aimed at preventing the progression to advanced AMD include supplementation with lutein and/or zeaxanthin and longchain polyunsaturated fatty acids. Patients who ask about these supplements and many do should be told that it is unknown at this time if prospective supplementation lowers their risk for visual acuity loss or for developing neovascular AMD. Although there are reports in the literature that these supplements are associated with lower risk of AMD and neovascular AMD, the reports merely describe associations, not the findings of cause and effect studies. 9 However, the associations have generated hypotheses for a future clinical trial known as AREDS-2. Table 1. Simplified AREDS Scale for Assessing 5- Year Risk of Advanced AMD Summed Number of Points 5-Year Risk 0 0.5% 1 3% 2 12% 3 25% 4 50% Point scale: Large drusen = 1 point for each eye Pigment abnormality = 1 point for each eye Advanced AMD in 1 eye = 2 points Sum up values 0 4 AMD = age-related macular degeneration; AREDS = Age-Related Eye Disease Study. Data from Ferris et al. 3 Table 2. Recommended Doses of AREDS Supplements Vitamin C: 500 mg Vitamin E: 400 IU Beta carotene: 15 mg Zinc oxide: 80 mg Cupric oxide: 2 mg Zinc was evaluated alone and also with antioxidants Copper supplementation was used to prevent the possibility of induced anemia from zinc AREDS = Age-Related Eye Disease Study. Data from Age-Related Eye Disease Study Research Group. 2 Johns Hopkins Advanced Studies in Ophthalmology n 33
3 MODIFICATION OF OTHER RISK FACTORS Except for smoking, which clearly increases the risk of AMD, 4-7 the associations of obesity and lack of regular exercise with AMD, and of increased intake of fruits and vegetables, fish, and certain fats with lower rates of AMD, do not demonstrate cause and effect. Therefore, patients should not be advised to modify their diets and get more exercise solely to lower their risk of AMD. Rather, they should be encouraged to implement these changes (and also quit smoking) for better cardiovascular and overall health and fitness. With regard to environmental risk factors, such as sun exposure, there is no evidence that sunglasses protect against AMD. However, because they do protect against cataract formation, they can be recommended if the lenses provide protection against ultraviolet rays. F i g u re. P re fe rential Hyperacuity Perimeter Map p i n g CNV = choroidal neovascularization. MONITORING FOR SIGNS OF NEOVASCULAR AMD Periodic monitoring of patients with the intermediate stage of AMD is essential in order to detect prog ression to advanced AMD, and specifically the development of neovascular lesions. Early detection is the key to minimizing the risk of visual acuity loss. Patient self-monitoring, in addition to regular ophthalmology visits, is integral to the timely identification of AMD progression. Patients should be taught to self-monitor 1 eye at a time for metamorphopsia and for scotoma formations, both of which would suggest the development of CNV. In the office, ophthalmologists can monitor patients for these symptoms with the Amsler grid or with preferential hyperacuity perimeter (PHP) testing. During the office visit, fundus biomicroscopy of the macular area is key to the detection of subretinal hemorrhage, hard exudates, and subretinal fluid, which are signs of CNV. Although frequently used to test visual acuity, the Amsler grid has several inherent flaws that contribute to the underestimation of neovascular abnormalities. One of these flaws is that the grid does not force the patient to fixate (on the central black dot), a circumstance that may yield a normal finding in a patient with CNV. In addition, the Amsler grid does not overcome the crowding or cortical completion phenomena. In a study in which visual acuity was regularly monitored with the Amsler grid, only 20% of patients who developed CNV still had visual acuity of 20/40 or better. 10 The remaining 80% of patients had already developed significant visual loss with subfoveal CNV. Unlike the Amsler grid, PHP testing overcomes the crowding phenomenon and the cortical completion effects seen with Amsler grid testing. Studies show that PHP testing can detect early CNV and may also be useful in AMD monitoring. 11 Testing is done by a machine that shows the patient a single dotted line with an area of artificial distortion that gets progressively smaller (Figure). When the elevation caused by CNV is larger than the area of artificial distortion, the patient will preferentially pick this spot of true distortion. The patient merely touches the screen of the PHP machine. When the test is completed, the machine will print a map of the central 14 degrees of the patient s visual field, reporting on more than 500 data points across the entire visual field of the macula. The process takes approximately 5 minutes per eye. Preferential hyperacuity perimeter testing is based on the concept of hyperacuity or Vernier acuity, which is the ability of humans to perceive minute differences in the relative spatial localization of 2 objects. The ability to discern 2 seconds of arc, which is equivalent to 0.03 minutes of arc or degrees or the width of a pencil viewed at 300 meters, is due to the exceptional sensitivity of the brain to detect minute shifts in the colinear arrangement of photoreceptors. By comparison, Snellen acuity of 20/15 is based on the ability to resolve 1 minute of arc, or degrees. When PHP findings were compared with retina specialists readings of stereoscopic color fundus photographs from 120 subjects with either the intermedi- 34 Vol. 4, No. 2 n March 2007
4 ate stage of AMD or recent-onset CNV, the sensitivity of the specialists in correctly detecting CNV was 70% versus 83% for the PHP machine. 11 Specificity (ie, saying there was no CNV present when there truly was none) was 95% for retina specialists versus 88% for the PHP machine alone. 11 Fl u o rescein angiography was used as the gold standard for detecting CNV in these patients and determining sensitivity and specificity. However, fluorescein angiography is not useful for monitoring patients with suspected CNV. Monitoring should focus on the symptoms and signs of CNV, including metamorphopsia, blurred vision, and scotoma formation, in addition to the presence of blood, lipid, or fluid on examination before ordering a fluorescein angiogram. Optical coherence tomography, which is useful in detecting subretinal fluid and retinal edema, can also be used to follow patients with suspected CNV. LASER STUDIES Several studies have examined laser therapy of drusen as a means of lowering the risk of developing CNV. Prompted by reports of drusen resorption in patients who had received laser therapy for other reasons, these studies postulated that drusen are the earliest form of AMD and that obliterating them by laser would reduce the risk of CNV. However, the results of these laser studies have been disappointing. In the unilateral arm of the Choro i d a l Neovascularization Prevention Trial (CNVPT), 41% of 120 eyes treated with focal argon green laser had a 50% reduction in the number of drusen at 6 months. 12 However, there was a significantly higher rate of CNV in the treated eyes (risk ratio, 4.86) than in the observed eyes, and this arm of the study was halted. The majority of the CNV was occult. In the bilateral arm of the CNVPT, 78% of 312 laser-treated eyes of 156 patients had a 50% reduction in the number of drusen at 6 months. 12 Again, more treated eyes developed CNV (risk estimate, 2.0) than observed eyes. The Prophylactic Treatment of Age-Re l a t e d Macular Degeneration trial, which used subthreshold diode laser, also found an excess of CNV in the unilateral arm, and study recruitment was stopped. 13 Although there was a reduction in drusen number, improvement of vision in some eyes, and the disappearance of drusen from the fovea, the investigators concluded that the increased risk of CNV did not warrant diode laser treatment. The 3-year Drusen Laser Study (DLS) found no statistically significant difference in the rates of CNV development or in the percentage of eyes that lost 3 or more lines of visual acuity. 14 However, the DLS also found that CNV onset was approximately 6 months earlier in laser-treated eyes than in eyes not treated with laser. Si m i l a r l y, the Complications of Age-Re l a t e d Macular Degeneration Trial, which enrolled patients with bilateral intermediate drusen, found no statistically significant differences in the percentage of lasertreated eyes or observed eyes that developed CNV or lost visual acuity at 5 years. 15 Rates of geographic atrophy were also similar in both groups 7.4% in lasertreated eyes and 7.8% in observed eyes. As these studies demonstrate, there is no proven benefit of laser treatment, and it is therefore not recommended for preventive therapy in patients with the intermediate stage of AMD. CONCLUSIONS Patients with the intermediate stage of AMD are at high risk of pro g ressing to advanced AMD. Although modification of potential risk factors for AMD, such as obesity and lack of exe rcise, is integral to better card i o- vascular and overall health, it should not be re c o m- mended solely to reduce the risk of pro g ression to a d vanced AMD. Howe ve r, all patients should be advised to quit smoking, re g a rdless of their risk for AMD. Patients with extensive intermediate drusen, 1 or more large drusen, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or visual acuity loss due to AMD in 1 eye should take high-dose antioxidants and zinc, as recommended by AREDS, to prevent disease progression. Because high doses of beta carotene increase the risk of lung cancer in those who smoke cigarettes, smokers should be advised to avoid beta carotene or take only low doses. Comprehensive ophthalmologists should consider enrolling patients with the intermediate stage of AMD in the AREDS-2 clinical trial at the nearest study site. They should also encourage patients to self-monitor their vision, 1 eye at a time, for early signs of CNV. C o m p re h e n s i ve ophthalmologists should monitor patients at risk with periodic eye examinations to detect CNV early and prevent loss of visual acuity. Johns Hopkins Advanced Studies in Ophthalmology n 35
5 REFERENCES 1. National Institutes of Health. Fact Sheet: age-related macular degeneration. Available at: about/researchresultsforthepublic/maculardegeneration.pdf #search=%22amd%208%20million%22. Accessed October 11, Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for a g e - related macular degeneration and vision loss: AREDS re p o rt no. 8. Arch Ophthalmol. 2001;119: Ferris FL, Davis MD, Clemons TE, et al. Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005;123: Klein R, Klein BE, Linton KL, DeMets DL. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol. 1993;137: Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114: Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l Age. Arch Ophthalmol. 1998;116: Khan JC, Thurlby DA, Shahid H, et al. Genetic Factors in AMD Study. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90: The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330: Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA. 1994;272: Olsen TW, Feng X, Kasper TJ, et al. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. O p h t h a l m o l o g y. 2004;111: Alster Y, Bressler NM, Bressler SB, et al. Preferential Hyperacuity Perimeter (PreView PHP) for Detecting Choroidal Neovascularization Study. Ophthalmology. 2005;112: Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology. 2003;110: Friberg TR, Musch DC, Lim JI, et al. Prophylactic Treatment of Age-Related Macular Degeneration Report Number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology. 2006;113:622.e Owens SL, Bunce C, Brannon AJ, et al. Drusen Laser Study Group. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the Drusen Laser Study. Am J Ophthalmol. 2006;141: Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age- Related Macular Degeneration Prevention Trial. Ophthalmology. 2006;113: Vol. 4, No. 2 n March 2007
Age- Related Macular Degeneration
Age- Related Macular Degeneration Age-Related Macular Degeneration (AMD) is the leading cause of blindness in the United States. It is caused by damage to a localized area of the central retina called
More informationVitreo-Retinal and Macular Degeneration Frequently Asked Questions
Vitreo-Retinal and Macular Degeneration Frequently Asked Questions What is a Vitreo-Retinal specialist? Retinal specialists are eye physicians and surgeons who focus on diseases in the back of the eye
More informationVitamins and Age-Related Macular Degeneration
Vitamins and Age-Related Macular Degeneration Comments and Opinions from the Retina Service at the Emory Eye Center Based on: Age-Related Eye Disease Study AREDS 1 and AREDS2 2,3 and other published data:
More informationNational PBM Drug Monograph
National PBM Drug Monograph Ocuvite PreserVision VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel April 2003 Introduction 1,2 Age-related macular degeneration (AMD)
More informationMacular Degeneration
Macular Degeneration Overview The macula is an area at the back of your eye that you use for seeing fine detail such as reading a book. Macular degeneration (MD) covers a number of conditions which affect
More informationGenetic Testing for Macular Degeneration
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe Long-term Effects of Laser Photocoagulation Treatment in Patients with Diabetic Retinopathy
The Long-term Effects of Laser Photocoagulation Treatment in Patients with Diabetic Retinopathy The Early Treatment Diabetic Retinopathy Follow-up Study Emily Y. Chew, MD, 1 Frederick L. Ferris III, MD,
More informationNutrition & Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a serious and currently untreatable disease that is the leading cause of acquired blindness among aging Americans. Both the severity and irreversibility of AMD
More informationAge-Related Macular Degeneration
Age-Related Macular Degeneration What You Should Know U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute The National Eye Institute (NEI) conducts and supports
More informationGeographic Atrophy: The Advanced Form of Dry AMD
Age-related macular degeneration (AMD) is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such
More informationWe are on WHAT ARE THE RISK FACTORS FOR MACULAR DEGENERATION?
We are on WHAT ARE THE RISK FACTORS FOR MACULAR DEGENERATION? Age Being 60 years of age and older Race Whites are much more likely to lose vision from AMD than Blacks Gender Women tend to be at greater
More informationYour guide to age-related macular degeneration
Your guide to age-related macular degeneration No one need face macular degeneration alone. For information and support call 0300 3030 111. Support throughout central vision loss The Macular Society is
More informationResults from the Age-Related Eye Disease Study
Results from the Age-Related Eye Disease Study Age-Related Eye Disease Study Table of Contents What is a Cataract?...4 What is Age-related Macular Degeneration?...4-6 Treatments...7 Results-Cataract...8
More informationINTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE DETAILED TABLE
Proposed Disease Severity Level No apparent Mild Non- Proliferative Moderate Nonproliferative Severe Non- Proliferative Proliferative INTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE
More informationVisual Disorders in Middle-Age and Elderly Patients with Diabetic Retinopathy
Medical Care for the Elderly Visual Disorders in Middle-Age and Elderly Patients with Diabetic Retinopathy JMAJ 46(1): 27 32, 2003 Shigehiko KITANO Professor, Department of Ophthalmology, Diabetes Center,
More informationCare of the Patient with Age-Related Macular Degeneration
OPTOMETRIC CLINICAL PRACTICE GUIDELINE Care of the Patient with Age-Related Macular Degeneration OPTOMETRY: THE PRIMARY EYE CARE PROFESSION Doctors of optometry are independent primary health care providers
More informationAlexandria Fairfax Sterling Leesburg 703-931-9100 703-573-8080 703-430-4400 703-858-3170
DIABETIC RETINOPATHY www.theeyecenter.com This pamphlet has been written to help people with diabetic retinopathy and their families and friends better understand the disease. It describes the cause, symptoms,
More informationIncidence of Exudative Age-Related Macular Degeneration among Elderly Americans
Incidence of Exudative Age-Related Macular Degeneration among Elderly Americans Jonathan C. Javitt, MD, MPH, 1 Zhiyuan Zhou, PhD, 2 Maureen G. Maguire, PhD, 2 Stuart L. Fine, MD, 3 Richard J. Willke, PhD
More informationAge-Related Macular Degeneration What You Should Know
Age-Related Macular Degeneration What You Should Know U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute B Contents What you should know about age-related
More informationMaking Vision a Health Priority. Speaker s Guide
Making Vision a Health Priority Speaker s Guide SLIDE 1 Introduction of the speaker. The purpose of this presentation is to provide information about vision changes that can occur with age and to talk
More informationOptic Disc Drusen. Normal Enlarged view of Optic Disc. Lumpy Appearance of Optic Disc. Optic Disc Drusen With Drusen
Optic Disc Drusen Your doctor has diagnosed you with optic disc drusen. Optic disc drusen are abnormal deposits of protein-like material in the optic disc the front part of the optic nerve. We do not know
More informationRecently, the Treatment of Age-Related Macular Degeneration
Photodynamic Therapy with Verteporfin (Visudyne): Impact on Ophthalmology and Visual Sciences Neil M. Bressler and Susan B. Bressler Recently, the Treatment of Age-Related Macular Degeneration with Photodynamic
More informationDIABETIC RETINOPATHY. Diabetes mellitus is an abnormality of the blood glucose metabolism due to altered
DIABETIC RETINOPATHY Diabetes mellitus Diabetes mellitus is an abnormality of the blood glucose metabolism due to altered insulin production or activity. There are two types diabetes mellitus- Insulin
More informationNational AMD & Low Vision Awareness Month- February 2016. Dr. Karuna Milind. Wellness Dept., Health India TPA.
National AMD & Low Vision Awareness Month- February 2016. Dr. Karuna Milind. Wellness Dept., Health India TPA. February is National AMD and Low Vision Awareness Month. Age-related macular degeneration
More informationGet Your Eyes Examined
1 Vision Changes You may notice vision changes with aging. Many changes are common and can often be corrected. As you get older, you are at higher risk of age-related eye diseases and conditions. Get Your
More informationNC DIVISION OF SERVICES FOR THE BLIND POLICIES AND PROCEDURES VOCATIONAL REHABILITATION
NC DIVISION OF SERVICES FOR THE BLIND POLICIES AND PROCEDURES VOCATIONAL REHABILITATION Section: E Revision History Revised 01/97; 05/03; 02/08; 04/08; 03/09; 05/09; 12/09; 01/11; 12/14 An individual is
More informationINFORMATION ON DARC: THE DIGITAL ANGIOGRAPHY READING CENTER
INFORMATION ON DARC: THE DIGITAL ANGIOGRAPHY READING CENTER 1 DIGITAL ANGIOGRAPHY READING CENTER Chairman/Medical Director Jason S. Slakter, M.D. Clinical Professor of Ophthalmology NYU School of Medicine
More informationLiterature Search on The Prevalence of Visual Disorders by Age Group in Older People
Literature Search on The Prevalence of Visual Disorders by Age Group in Older People Aggressive Research Intelligence Facility West Midlands Health Technology Assessment Collaboration October 2006 For
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationAge-Related Eye Diseases and Conditions. See Well for a Lifetime
Age-Related Eye Diseases and Conditions See Well for a Lifetime Vision Changes You may notice vision changes with aging. Many changes are common and can often be corrected. As you get older, you are at
More informationLaser Treatment in Patients with Bilateral Large Drusen
Laser Treatment in Patients with Bilateral Large Drusen The Complications of Age-Related Macular Degeneration Prevention Trial Complications of Age-Related Macular Degeneration Prevention Trial Research
More informationAge-Related Macular Degeneration. K. Bailey Freund, M.D. James M. Klancnik, Jr., M.D. Lawrence A. Yannuzzi, M.D. Bruce Rosenthal, O.D.
Age-Related Macular Degeneration K. Bailey Freund, M.D. James M. Klancnik, Jr., M.D. Lawrence A. Yannuzzi, M.D. Bruce Rosenthal, O.D. Contents Introduction 5 Anatomy of the Eye 6 The Eye 7 The Retina 9
More informationRadiation Therapy for Small Choroidal Neovascularization in Age-related Macular Degeneration
Radiation Therapy for Small Choroidal Neovascularization in Age-related Macular Degeneration Hideaki Matsuhashi,* Yasuko Noda,* Daisuke Takahashi* and Yasushi Mariya Departments of *Ophthalmology; Radiology,
More informationAn Informational Guide to CENTRAL RETINAL VEIN OCCLUSION
Science of CRVO www.scienceofcrvo.org An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION This brochure will guide you in understanding CRVO and the treatment options available to prevent vision loss.
More informationWhich eye conditions can avastin injections be used for?
What is avastin? Avastin is a drug that is licensed for the treatment of a certain type of colorectal cancer but can also be used to treat certain eye conditions by being injected into the eye. Although
More informationOptical Coherence Tomography Imaging and Quantitative Assessment for Monitoring Dry Age-related Macular Degeneration.
Imaging Optical Coherence Tomography Imaging and Quantitative Assessment for Monitoring Dry Age-related Macular Degeneration Albert J Augustin Head, Department of Ophthalmology, Staedtisches Klinikum Karlsruhe
More informationBlindness is one of the most feared
The Visually Impaired Patient ERIC A. ROSENBERG, MD, Weill Medical College of Cornell University, New York, New York LAURA C. SPERAZZA, OD, Jewish Guild for the Blind, New York, New York Blindness or low
More informationPhotographic Assessment of Baseline Fundus Morphologic Features in the Comparison of Age-Related Macular Degeneration Treatments Trials
Photographic Assessment of Baseline Fundus Morphologic Features in the Comparison of Age-Related Macular Degeneration Treatments Trials Juan E. Grunwald, MD, 1,2 Ebenezer Daniel, MBBS, PhD, 1,2 Gui-shuang
More informationAPRIL 8th 2016 Therapy
APRIL 8th 2016 Therapy 09.00-10.00 SESSION 1: Age-related Macular Degeneration Moderators: S. Sadda, D. Sarraf, K. Bailey Freund, E. Souied 09.00-09.15 Prospective SD OCT Analysis of PED Associated with
More informationACTVE INTERVENTIONAL CLINICAL TRIALS - 03/01/2015. Principal Investigator Study Title and Sponsor Study Description
Cornea and External Disease Service Li, Jennifer A Prospective, Multicenter Post-Approval Study (PAS) of VisionCare s Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients with Bilateral
More informationHEALTHY EYES. Type 2 diabetes. Information for patients. Disease Management Programme
HEALTHY EYES Information for patients Type 2 diabetes Disease Management Programme WHAT CAN I DO FOR HEALTHY EYES DESPITE MY TYPE 2 DIABETES? More and more people suffer from type 2 diabetes; among them,
More informationSpectral domain OCT used to view and quantify choroidal vascular congestion in new subretinal fluid following scleral buckling.
Spectral domain OCT used to view and quantify choroidal vascular congestion in new subretinal fluid following scleral buckling. Robert Gizicki MD, Mohamed Haji, Flavio Rezende Retina Service, Hôpital Maisonneuve-Rosemont,
More informationFigure 1. Flowchart of study selection process. AMD indicates age-related macular degeneration; RCT, randomized controlled trial.
2754 Abstracts initially identified through 7 databases 2704 Articles and abstracts excluded on the basis of title and abstract 37 Articles and 13 abstracts in English retrieved for detailed evaluation
More information82 Gilbert Street, Adelaide, SA, 5000 82 Gilbert Street, Adelaide, SA, 5000 W +61 8 8104 5293 M +61 417 818 658 W +61 8 8104 5200 M +61 414 661 994
ASX RELEASE Ellex Medical Lasers Limited (ASX:ELX) Adelaide, Australia Date: 14 September 2015 Release: Immediate Topic: Ellex releases first case study results for 2RT at major tradeshow Adelaide, Australia,
More informationDiabetic retinopathy - the facts
Diabetic retinopathy - the facts This leaflet sets out to answer some of your questions about the changes that may occur, or have occurred, in your eyes if you have diabetes. You might want to discuss
More informationPATIENT INFORMATION BOOKLET
(060110) VISIONCARE S IMPLANTABLE MINIATURE TELESCOPE ( BY DR. ISAAC LIPSHITZ ) AN INTRAOCULAR TELESCOPE FOR TREATING SEVERE TO PROFOUND VISION IMPAIRMENT DUE TO BILATERAL END-STAGE AGE-RELATED MACULAR
More informationScreening for Progressive Retinal Atrophy in Tibetan Terriers
Screening for Progressive Retinal Atrophy in Tibetan Terriers What is PRA? Progressive retinal atrophy (PRA) is the name given to a group of conditions that are inherited and result in a progressive loss
More informationPREVALENCE OF VISUAL IMPAIRMENT AMONG DIABETIC PATIENTS IN THE KUMBA URBAN AREA, CAMEROON
International Journal of Innovation and Applied Studies ISSN 2028-9324 Vol. 15 No. 4 May 2016, pp. 872-876 2016 Innovative Space of Scientific Research Journals http://www.ijias.issr-journals.org/ PREVALENCE
More informationEye Diseases. 1995-2014, The Patient Education Institute, Inc. www.x-plain.com otf30101 Last reviewed: 05/21/2014 1
Eye Diseases Introduction Some eye problems are minor and fleeting. But some lead to a permanent loss of vision. There are many diseases that can affect the eyes. The symptoms of eye diseases vary widely,
More informationFacts about diabetic macular oedema
Patient information medical retina services Facts about diabetic macular oedema What is diabetic macular oedema? Diabetic eye disease is a leading cause of blindness registration among working age adults
More informationOhr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results
December 10, 2015 Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference
More informationYou and Your Vision Health. Yes! Something More Can Be Done
You and Your Vision Health Can Yes! Something More Can Be Done You and Your Vision Health Yes! Something More Can Be Done You and Your Vision Health: Yes! Something More Can Be Done Copyright 2007, CNIB
More informationIntroduction Houston Retina Associates
1 2 Introduction This book was written by Houston Retina Associates to provide our patients with basic knowledge about retinal anatomy, an introduction to some of the diagnostic tests and treatments used
More informationUPDATE ON RESEARCH FOR RP TREATMENT: VITAMIN A PALMITATE, OMEGA-3-RICH FISH AND LUTEIN
UPDATE ON RESEARCH FOR RP TREATMENT: VITAMIN A PALMITATE, OMEGA-3-RICH FISH AND LUTEIN VITAMIN A PALMITATE / OMEGA-3-RICH FISH / LUTEIN Table of Contents Introduction 3 Important Guidelines from Dr. Berson
More informationCase Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
Case Reports in Medicine Volume 2012, Article ID 134636, 4 pages doi:10.1155/2012/134636 Case Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis Lei Liu and Fiona
More informationExperience and Quality Assurance MES Vision Provider Network nationwide Four
Experience and Quality Assurance MESVision has been providing exceptional vision care services to millions of individuals and thousands of employer groups since 1976 MESVision is the only medically led
More informationΗ δίαιτα στην πρόληψη του αγγειακού εγκεφαλικού επεισοδίου
ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥΔΩΝ «Η ΔΙΑΤΡΟΦΗ ΣΤΗΝ ΥΓΕΙΑ ΚΑΙ ΣΤΗ ΝΟΣΟ» Η δίαιτα στην πρόληψη του αγγειακού εγκεφαλικού επεισοδίου Γεώργιος Ντάιος Παθολογική Κλινική Πανεπιστημίου Θεσσαλίας Stroke Statistics
More informationAllen Dobson, PhD Health Economist. Co-Founder & President Dobson DaVanzo & Associates, LLC
Allen Dobson, PhD Health Economist Co-Founder & President Dobson DaVanzo & Associates, LLC Dobson DaVanzo & Associates, LLC Vienna, VA 703.260.1760 www.dobsondavanzo.com Discussion of Methods Used to Study
More informationThe Eyes Have It! by Carol A. Rice, Ph.D., R.N. Professor and Extension Health Specialist. Fall, 2001
The Eyes Have It! by Carol A. Rice, Ph.D., R.N. Professor and Extension Health Specialist Fall, 2001 Educational programs of the Texas A&M AgriLife Extension Service are open to all people without regard
More informationThis newest generation laser offers specific technological features and treatment options designed to substantially improve the retina laser therapy:
1 The latest generation of Quantel Medical Multispot Laser (Supra Scan 577) offers new technological features and treatment methods for improving retina laser therapy. Q uantel Medical Lasers give excellent
More informationTitle:Clinical and Optic Coherence Tomography Findings of Focal Choroidal Excavation in Chinese Patients
Author's response to reviews Title:Clinical and Optic Coherence Tomography Findings of Focal Choroidal Excavation in Chinese Patients Authors: Jie Guo (gjiexxx@163.com) Lu Zhong (luzhong_88@163.com) Chunhui
More informationRetinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease
Retinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease Eleonora (Nora) Lad, MD, PhD Assistant Professor of Ophthalmology, Vitreoretinal diseases Duke Center for Macular Diseases Duke University
More informationIncremental Cost Effectiveness of Laser Photocoagulation for Subfoveal Choroidal Neovascularization
Incremental Cost Effectiveness of Laser Photocoagulation for Subfoveal Choroidal Neovascularization Gary C. Brown, MD, MBA, 1,2 Melissa M. Brown, MD, MN, MBA, 2,3 Sanjay Sharma, MD, MSc, 2,4 Heidi Brown,
More informationNutrition during Lactation: What do Mom and Baby Need?
Nutrition during Lactation: What do Mom and Baby Need? Summary Nutritional needs during lactation are unique and one of the highest demands for good nutrition during a women s life. Many breastfeeding
More informationAvastin (Bevacizumab) Intravitreal Injection
Avastin (Bevacizumab) Intravitreal Injection This handout describes how Avastin may be used to treat wet age related macular degeneration (AMD) or macular edema due to retinal vascular disease such as
More informationColor Vision Defects - Color Blindness
Color Vision Defects - Color Blindness Introduction A color vision defect causes a person to see colors differently than most people. Color vision defects are sometimes called color blindness. There are
More informationNutrition and Parkinson s Disease: Can food have an impact? Sarah Zangerle, RD, CD Registered Dietitian Froedtert Memorial Lutheran Hospital
Nutrition and Parkinson s Disease: Can food have an impact? Sarah Zangerle, RD, CD Registered Dietitian Froedtert Memorial Lutheran Hospital Importance of Nutrition & Parkinson s Disease Good nutrition
More informationCompleted Clinical Research Trials Prema Abraham, M.D.
Completed Clinical Research Trials Prema Abraham, M.D. AMD Studies 2010 Present Principal Investigator: A Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous
More informationAppendix: Description of the DIETRON model
Appendix: Description of the DIETRON model Much of the description of the DIETRON model that appears in this appendix is taken from an earlier publication outlining the development of the model (Scarborough
More informationA Modified Semiautomatic Method for Measurement of Hyperfluorescence Area in Fluorescein Angiography
A Modified Semiautomatic Method for Measurement of Hyperfluorescence Area in Fluorescein Angiography Khalil Ghasemi Falavarjani, MD 1 Hanieh Mohammadreza, MSc 2 Sedigheh Marjaneh Hejazi, PhD 3 Masood Naseripour,
More informationPreventive Medicine and the Need for Routine Hearing Screening in Adults
Preventive Medicine and the Need for Routine Hearing Screening in Adults Brian Taylor Au.D., Director of Practice Development & Clinical Affairs, Unitron, Plymouth, MN Robert Tysoe, Marketing Consultant,
More informationThe 25 Lowest-Carb Vegetables
The 25 Lowest-Carb Vegetables It s not always easy to compare apples to oranges when it comes to carbs. Fruits and vegtables come in all shapes and sizes, and while it might seem like one is a lower-carb
More informationVitreomacular Traction: What s the Role of the Vitreoretinal Interface in this Disease?
Vitreomacular Traction: What s the Role of the Vitreoretinal Interface in this Disease? Robert A. Stoltz, M.D., Ph.D. Georgia Retina, P.C. Retinal Pearls 2013 Anatomy of the Vitreous Gel Physical Properties
More informationEye Department Baden-Baden. Prof. Dr. med. Frank Faude Dr. med. Susanne Faude Oxana Bräunlich. Ophthalmology specialists
E y e D e p a r t m e n t Prof. Dr. med. Frank Faude Dr. med. Susanne Faude Oxana Bräunlich Ophthalmology specialists Prof. Dr. med. Frank Faude Inpatient and outpatient treatment at the Stadtklinik Baden-Baden
More informationGLAUCOMA. American Academy of Ophthalmology
GLAUCOMA American Academy of Ophthalmology What is glaucoma? Glaucoma is a disease of the optic nerve, which is the part of the eye that carries the images we see to the brain. The optic nerve is made
More informationEye and Vision Care in the Patient-Centered Medical Home
1505 Prince Street, Alexandria, VA 22314 (703) 739-9200200 FAX: (703) 739-9497494 Eye and Vision Care in the Patient-Centered Medical Home The Patient Centered Medical Home (PCMH) is an approach to providing
More informationDiabetic Eye Screening Revised Grading Definitions
Diabetic Eye Screening Revised Grading Definitions Version 1.3, 1 November 2012 To provide guidance on revised grading definitions for the NHS Diabetic Eye Screening Programme Project/Category Document
More informationRetinal drusen: harbingers of age, safe havens for trouble
Age and Ageing 2009; 38: 648 654 C The Author 2009. Published by Oxford University Press [on behalf of the British Geriatrics Society]. doi: 10.1093/ageing/afp136 All rights reserved. For Permissions,
More informationDiabetes & blindness. due to DME BLINDNESS IN EUROPE
Diabetes & blindness due to DME BLINDNESS IN EUROPE Blindness is a life-changing disability which puts a heavy strain on the daily lives of sufferers, their families, and society at large. Today, 284 million
More information2013 Diabetes and Eye Disease Fact Sheet
The Georgia Department of Public Health 2013 Diabetes and Eye Disease Fact Sheet Diabetes is the leading cause of new cases of blindness among United States adults. 1-3 As Georgia s population ages and
More information25-hydroxyvitamin D: from bone and mineral to general health marker
DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate
More informationA Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa Purpose This study is currently patients. Verified by Neurotech Pharmaceuticals March 2007 Sponsored
More informationBRANCH RETINAL VEIN OCCLUSION (BRVO) AND LASER TREATMENT
INTRODUCTION: BRANCH RETINAL VEIN OCCLUSION (BRVO) AND LASER TREATMENT Branch Retinal Vein Occlusion (BRVO) involves the obstruction of a major venous blood vessel which prevents adequate drainage of blood
More informationInstitute of Applied Health Sciences. University of Aberdeen DATABASE REVIEW. Grampian University. Hospitals NHS Trust GRAMPIAN DIABETES
DATABASE REVIEW Grampian University Hospitals NHS Trust GRAMPIAN DIABETES SERVICES DATABASE Page 1 Contents Contents 2 Introduction 3 History 3 Overview of Database 3 Database Structure 4 Main Table Summary
More informationCharles C Wykoff, David M Brown, Maria E Maldonado, Daniel E Croft. Clinical science
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) Charles C Wykoff, David M Brown, Maria
More informationCan we make enemy soldiers blind using lasers? Lars Hode
Can we make enemy soldiers blind using lasers? by Lars Hode Swedish Laser-Medical Society Background: Lasers have long been used by our military forces: In distance measurements Target pointer in aircrafts
More informationTrends in Ophthalmology a Market Perspective. Matthias Karl, Michael Kempe
Trends in Ophthalmology a Market Perspective Matthias Karl, Michael Kempe 30.04.2013 Agenda 1 2 3 4 Role of Optical Technologies in Ophthalmology Demands of the Market - Trends in the Application Implications
More informationRetinal Update: November 2009 - March 2010
Retinal Update: November 2009 - March 2010 Diabetic Retinopathy Macular Degeneration: Age-related macular degeneration Macular Degeneration: Choroidal neovascularization Macular Disease: Central serous
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationTHE EYES IN CHARGE: FOR THE OPHTHALMOLOGIST Roberta A. Pagon, M.D. Division of Medical Genetics, CH-25, Children's Hospital /Medical Center, Box C5371, Seattle, WA 98105-0371 bpagon@u.washington.edu (206)
More informationAssessing the Accuracy of the Technology-based Eye Care Services (TECS) Protocol to a Standard Clinical Ophthalmic Exam
Assessing the Accuracy of the Technology-based Eye Care Services (TECS) Protocol to a Standard Clinical Ophthalmic Exam Introduction: As patients age, they are more at risk to lose vision. Routine eye
More informationCommissioning better eye care
Commissioning better eye care Clinical commissioning guidance from The College of Optometrists and The Royal College of Ophthalmologists Age-related macular degeneration Version: 1 Published: 25 Nov 2013
More informationPrinciples of Diagnosis MEDICAL DECISION-MAKING IN OPTOMETRIC PRACTICE. Medical Decision-Making. Medical Decision-Making.
MEDICAL DECISION-MAKING IN OPTOMETRIC PRACTICE Craig Thomas, O.D. 3900 West Wheatland Road Dallas, Texas 75237 972-780-7199 thpckc@yahoo.com Principles of Diagnosis The study of the art and science of
More information1981-1982 Ophthalmic Consultants Northwest, Seattle, Washington Retinal and vitreous consultation and surgery
EDUCATION Richard S. Munsen Jr., MD University of Washington Eye Institute HMC Box 359608, 325 Ninth Ave, Seattle WA 98104-2499 (206) 744-2020 for patient appointments, Fax (206) 897-4320 Academic phone
More informationMODERN CLINICAL OPTOMETRY BILLING & CODING THE MEDICAL EYE EXAMINATION. Definitions of Eye Examinations. Federal Government Definition
MODERN CLINICAL OPTOMETRY BILLING & CODING THE MEDICAL EYE EXAMINATION Craig Thomas, O.D. 3900 West Wheatland Road Dallas, Texas 75237 972-780-7199 thpckc@yahoo.com Definitions of Eye Examinations Optometry
More informationKeeping Your Eyes Healthy after Treatment for Childhood Cancer
Keeping Your Eyes Healthy after Treatment for Childhood Cancer High doses of radiation to the brain, eye, or eye socket (orbit) during treatment for childhood cancer can have a long-lasting affect on the
More informationWhat Eye Care Professionals Would Like Team Members to Know About Eye Health and Diabetes
What Eye Care Professionals Would Like Team Members to Know About Eye Health and Diabetes In this section, you will find an overview of key medical issues related to eye health and diabetes in order to
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationHealthcare Inspection. Quality of Care Issues Involving Manchester VA Medical Center and VA Boston Healthcare System
Department of Veterans Affairs Office of Inspector General Healthcare Inspection Quality of Care Issues Involving Manchester VA Medical Center and VA Boston Healthcare System Report No. 07-01119-196 September
More information